CANCER FACT SHEET 2022
CORPUS UTERI CANCER
ICD-10 C54

Belgian Cancer Registry

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*(1.05)^5).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

TABLE OF CONTENTS

1.1. Corpus uteri cancer incidence: by region

1.1.1. Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				All ages	ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-			
Females																							
Belgium	0	0	0	0	0	1	5	5	25	35	60	111	149	226	248	229	161	88	38	4	1,385		22.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.3]	[1.3]	[6.6]	[9.5]	[15.5]	[27.8]	[39.6]	[67.9]	[84.0]	[99.1]	[90.3]	[65.3]	[54.8]	[19.5]	[23.6]		(21.0; 23.4)
Brussels	0	0	0	0	0	0	0	0	3	5	10	12	6	16	17	19	7	5	3	0	103		21.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.7]	[12.4]	[26.8]	[35.6]	[20.2]	[64.3]	[79.7]	[110.2]	[53.7]	[49.7]	[52.0]	[0.0]	[16.6]		(17.0; 25.3)
Flanders	0	0	0	0	0	1	3	4	11	24	33	64	94	140	150	150	110	51	21	2	858		22.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.9]	[5.1]	[11.6]	[14.6]	[26.9]	[41.9]	[70.8]	[86.4]	[104.9]	[98.2]	[59.9]	[49.3]	[16.6]	[25.4]		(21.4; 24.4)
Wallonia	0	0	0	0	0	0	2	1	11	6	17	35	49	70	81	60	44	32	14	2	424		21.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[0.9]	[9.5]	[5.0]	[13.7]	[27.6]	[40.0]	[63.7]	[80.8]	[84.6]	[82.7]	[81.0]	[66.6]	[31.4]	[22.7]		(19.1; 23.2)

1.2. Corpus uteri cancer incidence: by tumour stage

1.2.1. Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	70 [2.4]	482 [34.3]	310 [48.9]	862 [14.7]	13.8 (12.9; 14.7)
II	5 [0.2]	19 [1.4]	28 [4.4]	52 [0.9]	0.8 (0.6; 1.0)
III	4 [0.1]	64 [4.6]	45 [7.1]	113 [1.9]	1.8 (1.5; 2.1)
IV	11 [0.4]	56 [4.0]	44 [6.9]	111 [1.9]	1.8 (1.4; 2.1)
X/NA	41 [1.4]	113 [8.1]	93 [14.7]	247 [4.2]	4.0 (3.5; 4.5)

1.2.2. Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	97 [3.3]	508 [36.2]	299 [47.2]	904 [15.4]	14.7 (13.7; 15.6)
II	4 [0.1]	40 [2.9]	30 [4.7]	74 [1.3]	1.2 (0.9; 1.5)
III	9 [0.3]	89 [6.3]	62 [9.8]	160 [2.7]	2.6 (2.2; 3.0)
IV	8 [0.3]	37 [2.6]	20 [3.2]	65 [1.1]	1.1 (0.8; 1.3)
X/NA	13 [0.4]	60 [4.3]	109 [17.2]	182 [3.1]	2.7 (2.3; 3.1)

1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	97 [3.3]	511 [36.4]	327 [51.6]	935 [15.9]	15.1 (14.1; 16.1)
II	4 [0.1]	41 [2.9]	37 [5.8]	82 [1.4]	1.3 (1.0; 1.6)
III	9 [0.3]	90 [6.4]	76 [12.0]	175 [3.0]	2.8 (2.4; 3.2)
IV	13 [0.4]	70 [5.0]	48 [7.6]	131 [2.2]	2.1 (1.7; 2.5)
X/NA	8 [0.3]	22 [1.6]	32 [5.0]	62 [1.1]	1.0 (0.7; 1.2)

1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	N[CR]				ESR2013 (95%CI)
	15-54	**55-74**	**75+**	**All ages**	
Endometrioid carcinoma	81 [2.8]	552 [39.3]	340 [53.6]	973 [16.6]	15.6 (14.7; 16.6)
Serous carcinoma	7 [0.2]	74 [5.3]	65 [10.3]	146 [2.5]	2.3 (2.0; 2.7)
Other and unspecified	43 [1.5]	108 [7.7]	115 [18.1]	266 [4.5]	4.2 (3.7; 4.7)

1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	Stage	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages	
Endometrioid carcinoma	I	68 [2.3]	429 [30.6]	248 [39.1]	745 [12.7]	12.0 (11.2; 12.9)
	II	2 [0.1]	31 [2.2]	20 [3.2]	53 [0.9]	0.8 (0.6; 1.1)
	III	5 [0.2]	56 [4.0]	40 [6.3]	101 [1.7]	1.6 (1.3; 1.9)
	IV	4 [0.1]	21 [1.5]	15 [2.4]	40 [0.7]	0.6 (0.4; 0.8)
	X/NA	2 [0.1]	15 [1.1]	17 [2.7]	34 [0.6]	0.5 (0.3; 0.7)
Serous carcinoma	I	3 [0.1]	30 [2.1]	23 [3.6]	56 [1.0]	0.9 (0.7; 1.1)
	II	0 [0.0]	3 [0.2]	5 [0.8]	8 [0.1]	0.1 (0.0; 0.2)
	III	3 [0.1]	16 [1.1]	20 [3.2]	39 [0.7]	0.6 (0.4; 0.8)
	IV	1 [0.0]	24 [1.7]	15 [2.4]	40 [0.7]	0.6 (0.4; 0.8)
	X/NA	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.1 (0.0; 0.1)
Other and unspecified	I	26 [0.9]	52 [3.7]	56 [8.8]	134 [2.3]	2.1 (1.8; 2.5)
	II	2 [0.1]	7 [0.5]	12 [1.9]	21 [0.4]	0.3 (0.2; 0.5)
	III	1 [0.0]	18 [1.3]	16 [2.5]	35 [0.6]	0.6 (0.4; 0.7)
	IV	8 [0.3]	25 [1.8]	18 [2.8]	51 [0.9]	0.8 (0.6; 1.0)
	X/NA	6 [0.2]	6 [0.4]	13 [2.1]	25 [0.4]	0.4 (0.2; 0.5)

Belgian Cancer Registry

2.1. Corpus uteri cancer incidence trends: by region

2.1.1. Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Belgium	**N**	1,431	1,383	1,348	1,393	1,466	1,462	1,419	1,430	1,449	1,391	1,464	1,458	1,445	1,400	1,441	1,347	1,308	1,421	1,385		
	CR	27.0	25.9	25.1	25.8	26.9	26.7	25.7	25.6	25.8	24.6	25.8	25.6	25.2	24.3	24.9	23.2	22.4	24.3	23.6		
	ESR2013	28.1	26.9	26.1	26.6	27.5	27.2	26.0	26.0	26.0	24.4	25.5	25.3	25.0	23.7	24.1	22.3	21.3	22.9	22.2	-1.3 (-1.6; -1.0)	2004-2022
Brussels	**N**	111	105	102	105	116	122	113	100	80	125	106	109	115	111	122	95	99	133	103		
	CR	21.4	20.1	19.3	19.6	21.4	22.1	20.1	17.3	13.7	21.1	17.8	18.1	18.9	18.2	19.9	15.4	16.0	21.4	16.6		
	ESR2013	23.8	22.6	21.9	22.9	24.4	25.8	23.9	20.5	16.9	25.8	21.5	22.2	23.9	22.7	25.1	18.6	19.6	26.8	21.2	-0.3 (-1.3; 0.8)	2004-2022
Flanders	**N**	862	831	838	859	911	894	830	859	917	855	881	887	872	837	830	834	799	853	858		
	CR	28.3	27.1	27.2	27.7	29.2	28.4	26.2	26.9	28.5	26.5	27.1	27.2	26.6	25.4	25.1	25.1	23.9	25.4	25.4		
	ESR2013	29.0	27.4	27.6	27.9	29.0	28.2	25.7	26.3	27.8	25.1	25.8	25.9	25.1	23.8	23.0	23.0	21.7	22.7	22.9	-1.5 (-1.8; -1.2)	2004-2022
Wallonia	**N**	458	447	408	429	439	446	476	471	452	411	477	462	458	452	489	418	410	435	424		
	CR	26.3	25.6	23.2	24.3	24.7	25.0	26.5	26.0	24.8	22.5	26.0	25.1	24.8	24.4	26.4	22.5	22.0	23.3	22.7		
	ESR2013	27.7	27.0	24.6	25.1	25.5	25.5	26.9	26.7	25.3	22.8	25.8	24.9	24.9	23.6	25.6	21.8	20.9	22.1	21.1	-1.2 (-1.6; -0.7)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Corpus uteri cancer incidence trends: by tumour stage

2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
I	N	983	893	885	975	935		
	CR	17.0	15.4	15.2	16.7	15.9		
	ESR2013	16.6	15.0	14.6	15.9	15.1	0.7 (0.4; 1.1)	2004-2022
							4.1 (3.2; 4.9)	2004-2012
							-1.8 (-2.5; -1.2)	2013-2022
II	N	71	82	64	77	82		
	CR	1.2	1.4	1.1	1.3	1.4		
	ESR2013	1.1	1.3	1.0	1.2	1.3	-2.5 (-3.5; -1.5)	2004-2022
III	N	178	173	162	171	175		
	CR	3.1	3.0	2.8	2.9	3.0		
	ESR2013	3.0	2.8	2.7	2.7	2.8	0.6 (-0.3; 1.5)	2004-2022
IV	N	113	115	123	128	131		
	CR	2.0	2.0	2.1	2.2	2.2		
	ESR2013	1.8	1.9	2.0	2.0	2.1	3.7 (2.7; 4.8)	2004-2022
X/NA	N	96	84	74	70	62		
	CR	1.7	1.4	1.3	1.2	1.1		
	ESR2013	1.5	1.3	1.1	1.0	1.0	-12.0 (-13.1; -11.0)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Corpus uteri cancer incidence trends: by tumour type

2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

type		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Endometrioid carcinoma	**N**	875	850	862	899	973	1,022	940	997	1,019	964	1,023	1,013	1,005	993	993	944	943	1,022	973		
	CR	16.5	15.9	16.1	16.6	17.9	18.6	17.0	17.9	18.1	17.1	18.0	17.8	17.5	17.3	17.2	16.3	16.2	17.5	16.6		
	ESR2013	17.3	16.6	16.8	17.3	18.4	19.0	17.3	18.2	18.4	17.1	17.9	17.7	17.5	16.8	16.7	15.7	15.4	16.6	15.6	-0.5 (-0.8; -0.1)	2004-2022
																					1.2 (0.1; 2.2)	2004-2011
																					-1.2 (-2.8; 0.4)	2012-2015
																					-1.7 (-2.7; -0.6)	2016-2022
Serous carcinoma	**N**	47	52	53	74	78	98	82	91	93	96	114	109	128	119	147	117	123	143	146		
	CR	0.9	1.0	1.0	1.4	1.4	1.8	1.5	1.6	1.7	1.7	2.0	1.9	2.2	2.1	2.5	2.0	2.1	2.4	2.5		
	ESR2013	0.9	1.0	1.0	1.4	1.4	1.8	1.4	1.6	1.7	1.7	2.0	1.9	2.2	2.0	2.4	1.9	2.0	2.3	2.3	5.6 (4.6; 6.7)	2004-2022
																					13.2 (8.5; 18.1)	2004-2009
																					2.4 (-2.0; 6.9)	2010-2013
																					3.1 (1.0; 5.2)	2014-2022
Other and unspecified	**N**	509	481	433	420	415	342	397	342	337	331	327	336	312	288	301	286	242	256	266		
	CR	9.6	9.0	8.1	7.8	7.6	6.2	7.2	6.1	6.0	5.9	5.8	5.9	5.4	5.0	5.2	4.9	4.1	4.4	4.5		
	ESR2013	9.9	9.2	8.3	7.9	7.7	6.3	7.2	6.1	5.9	5.7	5.7	5.7	5.3	4.8	5.0	4.6	3.9	4.0	4.2	-5.0 (-5.6; -4.4)	2004-2022
																					-8.6 (-12.0; -5.0)	2004-2007
																					-4.3 (-4.8; -3.7)	2008-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Corpus uteri cancer incidence trends: by age group

2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, %	(95%CI)	Period
15-54	N	160	155	158	160	162	156	148	140	122	141	151	157	147	128	127	120	105	119	131			
	CR	5.7	5.5	5.6	5.6	5.7	5.4	5.1	4.8	4.2	4.8	5.2	5.4	5.1	4.4	4.4	4.2	3.6	4.1	4.5			
	ESR2013	5.9	5.7	5.7	5.7	5.7	5.5	5.1	4.8	4.2	4.8	5.1	5.4	5.0	4.4	4.4	4.2	3.7	4.2	4.6	-2.0	(-2.7; -1.3)	2004-2022
55-74	N	854	804	813	812	820	836	785	806	854	744	772	820	801	775	825	744	720	772	734			
	CR	78.0	72.8	73.2	72.7	72.8	73.3	67.9	68.6	71.5	61.4	62.8	65.6	62.8	59.4	62.0	54.9	52.3	55.4	52.3			
	ESR2013	78.0	73.1	73.7	73.3	73.6	74.1	69.2	69.9	72.9	62.7	64.3	67.0	64.7	60.7	62.9	55.6	52.8	55.7	52.7	-2.1	(-2.5; -1.8)	2004-2022
																					-1.4	(-2.0; -0.8)	2004-2015
																					-3.2	(-4.2; -2.2)	2016-2022
75+	N	417	424	377	421	484	470	486	484	473	506	541	481	497	497	489	483	483	530	520			
	CR	80.2	79.8	69.2	75.5	85.0	81.3	82.8	81.6	78.8	83.7	88.7	77.9	80.6	81.1	80.0	78.6	77.8	85.6	82.0			
	ESR2013	78.8	78.9	68.7	75.2	84.6	80.9	82.6	82.2	78.8	83.6	89.6	78.8	83.3	82.7	81.7	81.3	81.2	87.3	85.3	0.6	(0.1; 1.0)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Corpus uteri cancer prevalence: by region

3.1.1. Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022

Region		Females			
		1-year	**5-year**	**10-year**	**15-year**
Belgium	N	1,310	5,502	9,908	13,458
	CR	22.1	92.7	166.9	227
	ESR2013	20.7	86.3	154.1	207.6
Brussels	N	96	423	748	969
	CR	15.2	66.8	118.2	153.1
	ESR2013	19.3	83.8	147.8	191.9
Flanders	N	812	3,354	6,103	8,364
	CR	23.7	98.0	178.3	244.4
	ESR2013	21.3	87.1	156.6	212.7
Wallonia	N	402	1,725	3,057	4,125
	CR	21.4	91.7	162.5	219.3
	ESR2013	19.7	84.9	149.9	200.8

Belgian Cancer Registry

4.1. Corpus uteri cancer survival: by region

4.1.1. Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2018-2022

Net Survival Probability, 2018-2022					
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**
Females					
Belgium	**All ages**	13,995	91.2% (90.7%; 91.8%)	83.5% (82.7%; 84.3%)	80.9% (79.9%; 81.9%)
	15-54	1,141	96.0% (94.9%; 97.2%)	90.8% (89.1%; 92.6%)	88.5% (86.5%; 90.5%)
	55-74	7,680	94.4% (93.9%; 95.0%)	87.4% (86.5%; 88.2%)	84.3% (83.3%; 85.4%)
	75+	5,005	85.0% (83.8%; 86.2%)	75.6% (73.9%; 77.4%)	73.6% (71.3%; 76.0%)
Brussels	**All ages**	1,107	90.1% (88.1%; 92.2%)	81.2% (78.2%; 84.2%)	80.4% (76.8%; 84.1%)
	15-54	146	95.3% (91.9%; 98.9%)	90.0% (85.1%; 95.2%)	87.6% (81.9%; 93.6%)
	55-74	559	93.5% (91.3%; 95.7%)	84.6% (81.3%; 88.0%)	80.4% (76.4%; 84.5%)
	75+	387	83.2% (78.8%; 87.8%)	72.7% (66.4%; 79.5%)	77.3% (69.2%; 86.3%)
Flanders	**All ages**	8,468	91.4% (90.7%; 92.1%)	84.7% (83.7%; 85.8%)	82.8% (81.5%; 84.2%)
	15-54	631	95.8% (94.2%; 97.4%)	90.5% (88.2%; 93.0%)	88.0% (85.3%; 90.8%)
	55-74	4,603	94.8% (94.1%; 95.5%)	88.5% (87.4%; 89.6%)	86.5% (85.2%; 87.8%)
	75+	3,128	85.4% (83.9%; 86.9%)	77.6% (75.5%; 79.9%)	76.0% (73.1%; 79.1%)
Wallonia	**All ages**	4,420	91.1% (90.2%; 92.1%)	81.8% (80.4%; 83.3%)	77.4% (75.6%; 79.2%)
	15-54	364	96.8% (95.0%; 98.7%)	91.7% (88.7%; 94.7%)	89.6% (86.2%; 93.1%)

		Net Survival Probability, 2018-2022			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**
	55-74	2,518	94.0% (93.0%; 95.0%)	86.0% (84.5%; 87.5%)	81.2% (79.4%; 83.1%)
	75+	1,490	84.7% (82.5%; 86.9%)	72.0% (68.9%; 75.3%)	67.6% (63.4%; 72.0%)

4.2. Corpus uteri cancer survival: by tumour type and tumour stage

4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2018-2022

type	cStage	N at risk	Net Survival Probability, 2018-2022				
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	13,995	91.2% (90.7%; 91.8%)	86.4% (85.7%; 87.1%)	83.5% (82.7%; 84.3%)	82.0% (81.1%; 83.0%)	80.9% (79.9%; 81.9%)
	I	6,068	98.7% (98.1%; 99.2%)	96.9% (96.2%; 97.7%)	95.3% (94.3%; 96.3%)	94.2% (93.0%; 95.5%)	93.4% (91.9%; 94.9%)
	II	414	88.8% (85.3%; 92.5%)	81.4% (76.9%; 86.2%)	77.2% (71.9%; 82.7%)	73.3% (67.4%; 79.7%)	69.4% (62.7%; 76.8%)
	III	881	79.6% (76.7%; 82.5%)	68.6% (65.2%; 72.2%)	59.1% (55.4%; 63.0%)	54.4% (50.4%; 58.7%)	53.0% (48.6%; 57.7%)
	IV	898	45.6% (42.4%; 49.1%)	30.6% (27.6%; 34.0%)	23.6% (20.7%; 26.9%)	21.1% (18.3%; 24.4%)	19.0% (16.1%; 22.4%)
	X/NA	5,745	92.4% (91.6%; 93.3%)	87.1% (86.1%; 88.2%)	84.6% (83.4%; 85.8%)	83.3% (82.0%; 84.7%)	82.3% (80.8%; 83.8%)
Endometrioid carcinoma	All	9,848	96.3% (95.8%; 96.8%)	94.5% (93.8%; 95.2%)	93.0% (92.1%; 93.8%)	92.2% (91.2%; 93.1%)	91.5% (90.4%; 92.7%)
	I	4,807	100.0% (99.5%; 100.5%)	99.9% (99.1%; 100.6%)	99.3% (98.3%; 100.3%)	99.2% (97.9%; 100.4%)	98.5% (96.9%; 100.1%)
	II	263	92.4% (88.6%; 96.5%)	86.5% (81.3%; 92.0%)	83.2% (77.1%; 89.9%)	78.9% (71.7%; 86.7%)	76.5% (68.5%; 85.3%)
	III	496	85.3% (81.9%; 88.9%)	78.8% (74.7%; 83.2%)	71.6% (66.9%; 76.8%)	66.4% (61.1%; 72.2%)	66.1% (60.2%; 72.7%)
	IV	326	54.0% (48.7%; 59.9%)	41.1% (35.8%; 47.1%)	34.1% (28.9%; 40.3%)	32.1% (26.8%; 38.4%)	30.9% (25.4%; 37.6%)
	X/NA	3,956	96.9% (96.2%; 97.7%)	94.9% (93.9%; 95.9%)	93.4% (92.2%; 94.7%)	92.7% (91.2%; 94.1%)	92.2% (90.5%; 93.9%)
Serous carcinoma	All	1,240	81.3% (79.0%; 83.7%)	65.3% (62.4%; 68.3%)	56.6% (53.5%; 59.9%)	51.7% (48.4%; 55.2%)	47.5% (43.9%; 51.3%)
	I	385	96.8% (94.3%; 99.4%)	83.9% (79.5%; 88.5%)	74.6% (69.2%; 80.4%)	69.9% (63.9%; 76.5%)	67.0% (60.2%; 74.6%)
	II	45	N<50	N<50	N<50	N<50	N<50
	III	157	77.3% (70.6%; 84.7%)	57.7% (49.9%; 66.8%)	43.4% (35.3%; 53.4%)	38.3% (30.0%; 49.0%)	31.5% (22.8%; 43.5%)
	IV	205	47.5% (41.0%; 55.0%)	29.3% (23.5%; 36.7%)	22.2% (16.6%; 29.5%)	19.0% (13.7%; 26.5%)	13.5% (8.6%; 21.3%)
	X/NA	448	83.4% (79.6%; 87.3%)	66.5% (61.8%; 71.6%)	59.7% (54.7%; 65.1%)	54.1% (48.9%; 59.8%)	50.8% (45.4%; 56.8%)
Other and unspecified	All	2,923	78.3% (76.7%; 79.9%)	68.2% (66.3%; 70.1%)	63.0% (61.0%; 65.1%)	60.7% (58.5%; 62.9%)	59.1% (56.8%; 61.5%)
	I	877	92.1% (90.0%; 94.3%)	86.8% (84.0%; 89.6%)	82.3% (78.9%; 85.8%)	77.7% (73.8%; 81.9%)	76.6% (72.1%; 81.4%)

type	cStage	N at risk	Net Survival Probability, 2018-2022				
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	II	106	76.8% (68.3%; 86.2%)	68.0% (58.3%; 79.4%)	65.7% (55.2%; 78.2%)	63.3% (52.0%; 77.1%)	60.5% (47.7%; 76.7%)
	III	228	68.5% (62.5%; 75.1%)	54.0% (47.4%; 61.5%)	42.5% (35.9%; 50.3%)	39.1% (32.4%; 47.2%)	38.2% (31.2%; 46.6%)
	IV	367	37.1% (32.3%; 42.5%)	22.1% (18.1%; 27.0%)	15.2% (11.7%; 19.7%)	12.8% (9.4%; 17.3%)	11.6% (8.3%; 16.2%)
	X/NA	1,350	82.2% (80.0%; 84.5%)	71.2% (68.5%; 74.0%)	66.8% (63.9%; 69.8%)	65.6% (62.5%; 68.8%)	63.8% (60.5%; 67.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2018-2022

type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
			Net Survival Probability, 2018-2022				
Corpus uteri	All	13,995	91.2% (90.7%; 91.8%)	86.4% (85.7%; 87.1%)	83.5% (82.7%; 84.3%)	82.0% (81.1%; 83.0%)	80.9% (79.9%; 81.9%)
	I	9,231	99.9% (99.6%; 100.2%)	99.0% (98.5%; 99.6%)	98.1% (97.4%; 98.8%)	97.7% (96.8%; 98.5%)	97.3% (96.3%; 98.4%)
	II	693	93.3% (91.1%; 95.7%)	86.8% (83.7%; 90.1%)	83.0% (79.3%; 86.9%)	79.7% (75.5%; 84.3%)	78.5% (73.7%; 83.7%)
	III	1,490	88.8% (87.0%; 90.6%)	77.4% (75.1%; 79.9%)	68.5% (65.7%; 71.3%)	64.4% (61.4%; 67.6%)	60.6% (57.2%; 64.1%)
	IV	508	66.1% (62.0%; 70.5%)	45.6% (41.3%; 50.4%)	38.4% (34.0%; 43.3%)	33.3% (28.9%; 38.3%)	28.9% (24.5%; 34.2%)
	X/NA	2,081	59.8% (57.6%; 62.1%)	46.8% (44.5%; 49.3%)	40.6% (38.1%; 43.2%)	37.6% (35.1%; 40.4%)	35.8% (33.1%; 38.7%)
Endometrioid carcinoma	All	9,848	96.3% (95.8%; 96.8%)	94.5% (93.8%; 95.2%)	93.0% (92.1%; 93.8%)	92.2% (91.2%; 93.1%)	91.5% (90.4%; 92.7%)
	I	7,368	100.7% (100.4%; 101.0%)	101.1% (100.6%; 101.6%)	100.9% (100.3%; 101.6%)	101.1% (100.3%; 102.0%)	101.1% (100.1%; 102.2%)
	II	444	96.9% (94.6%; 99.3%)	93.3% (89.9%; 96.7%)	91.2% (87.1%; 95.6%)	88.7% (83.6%; 94.1%)	89.2% (83.4%; 95.4%)
	III	862	91.8% (89.7%; 93.9%)	87.3% (84.6%; 90.0%)	80.8% (77.6%; 84.2%)	77.1% (73.4%; 81.0%)	73.0% (68.8%; 77.6%)
	IV	139	77.4% (70.3%; 85.1%)	68.4% (60.5%; 77.4%)	62.5% (54.0%; 72.4%)	57.0% (47.9%; 67.8%)	53.0% (43.4%; 64.8%)
	X/NA	1,035	70.8% (67.8%; 73.9%)	57.5% (54.1%; 61.1%)	51.0% (47.3%; 54.9%)	47.2% (43.4%; 51.3%)	44.9% (40.9%; 49.4%)
Serous carcinoma	All	1,240	81.3% (79.0%; 83.7%)	65.3% (62.4%; 68.3%)	56.6% (53.5%; 59.9%)	51.7% (48.4%; 55.2%)	47.5% (43.9%; 51.3%)
	I	493	98.8% (96.9%; 100.7%)	90.3% (86.9%; 93.8%)	84.0% (79.7%; 88.4%)	79.1% (74.1%; 84.3%)	76.1% (70.5%; 82.1%)
	II	75	92.6% (85.6%; 100.2%)	79.5% (69.3%; 91.1%)	67.0% (55.3%; 81.2%)	65.8% (53.4%; 81.0%)	61.0% (47.4%; 78.4%)
	III	260	92.2% (88.4%; 96.1%)	66.6% (60.6%; 73.2%)	52.0% (45.5%; 59.5%)	45.6% (38.8%; 53.6%)	39.7% (32.7%; 48.3%)
	IV	162	67.2% (60.1%; 75.1%)	43.5% (36.1%; 52.4%)	33.1% (26.0%; 42.1%)	23.3% (16.8%; 32.3%)	14.9% (9.4%; 23.7%)
	X/NA	250	41.3% (35.4%; 48.2%)	24.3% (19.1%; 30.8%)	19.1% (14.3%; 25.5%)	17.5% (12.8%; 24.0%)	15.0% (10.3%; 21.9%)
Other and unspecified	All	2,923	78.3% (76.7%; 79.9%)	68.2% (66.3%; 70.1%)	63.0% (61.0%; 65.1%)	60.7% (58.5%; 62.9%)	59.1% (56.8%; 61.5%)
	I	1,378	96.0% (94.6%; 97.3%)	91.0% (89.1%; 93.0%)	87.9% (85.6%; 90.3%)	85.8% (83.1%; 88.6%)	84.5% (81.4%; 87.7%)
	II	174	84.5% (78.7%; 90.6%)	73.7% (66.6%; 81.6%)	69.3% (61.5%; 78.0%)	63.2% (54.9%; 72.9%)	59.6% (50.6%; 70.2%)
	III	368	79.5% (75.2%; 84.1%)	62.1% (56.9%; 67.8%)	51.2% (45.7%; 57.4%)	48.0% (42.2%; 54.6%)	45.9% (39.7%; 53.0%)
	IV	208	57.5% (51.0%; 64.8%)	31.9% (25.9%; 39.2%)	25.9% (20.2%; 33.2%)	24.4% (18.7%; 31.9%)	22.8% (16.9%; 30.6%)

| type | pStage | N at risk | Net Survival Probability, 2018-2022 | | | | |
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	X/NA	798	51.2% (47.6%; 55.0%)	39.9% (36.3%; 43.9%)	33.7% (30.0%; 37.7%)	31.4% (27.7%; 35.6%)	30.2% (26.3%; 34.7%)

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2018-2022

type	Stage	N at risk	Net Survival Probability, 2018-2022				
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	13,995	91.2% (90.7%; 91.8%)	86.4% (85.7%; 87.1%)	83.5% (82.7%; 84.3%)	82.0% (81.1%; 83.0%)	80.9% (79.9%; 81.9%)
	I	9,479	99.3% (99.0%; 99.7%)	98.2% (97.6%; 98.7%)	96.9% (96.2%; 97.7%)	96.5% (95.6%; 97.4%)	96.0% (95.0%; 97.1%)
	II	742	90.2% (87.7%; 92.8%)	83.4% (80.1%; 86.8%)	79.1% (75.3%; 83.0%)	75.9% (71.7%; 80.5%)	75.0% (70.3%; 80.1%)
	III	1,630	84.4% (82.5%; 86.4%)	73.0% (70.6%; 75.5%)	64.5% (61.8%; 67.3%)	60.3% (57.4%; 63.4%)	56.2% (53.0%; 59.7%)
	IV	1,124	51.2% (48.2%; 54.3%)	34.1% (31.3%; 37.2%)	26.8% (24.1%; 29.8%)	23.2% (20.5%; 26.2%)	20.4% (17.7%; 23.5%)
	X/NA	1,028	71.9% (68.9%; 75.0%)	58.9% (55.6%; 62.5%)	54.5% (51.0%; 58.3%)	50.9% (47.2%; 54.9%)	49.4% (45.5%; 53.7%)
Endometrioid carcinoma	All	9,848	96.3% (95.8%; 96.8%)	94.5% (93.8%; 95.2%)	93.0% (92.1%; 93.8%)	92.2% (91.2%; 93.1%)	91.5% (90.4%; 92.7%)
	I	7,534	100.4% (100.0%; 100.7%)	100.4% (99.9%; 100.9%)	100.0% (99.3%; 100.7%)	100.2% (99.3%; 101.1%)	100.1% (99.0%; 101.3%)
	II	475	94.7% (92.1%; 97.4%)	89.9% (86.3%; 93.7%)	86.6% (82.3%; 91.2%)	83.7% (78.5%; 89.2%)	84.1% (78.4%; 90.3%)
	III	935	88.2% (85.9%; 90.6%)	82.5% (79.6%; 85.5%)	76.2% (72.8%; 79.7%)	72.1% (68.4%; 76.1%)	67.8% (63.4%; 72.4%)
	IV	387	58.3% (53.4%; 63.6%)	46.1% (41.1%; 51.7%)	38.8% (33.8%; 44.6%)	35.7% (30.6%; 41.6%)	33.4% (28.1%; 39.7%)
	X/NA	517	81.5% (77.8%; 85.4%)	70.5% (66.0%; 75.4%)	66.4% (61.5%; 71.8%)	61.7% (56.3%; 67.5%)	59.3% (53.6%; 65.7%)
Serous carcinoma	All	1,240	81.3% (79.0%; 83.7%)	65.3% (62.4%; 68.3%)	56.6% (53.5%; 59.9%)	51.7% (48.4%; 55.2%)	47.5% (43.9%; 51.3%)
	I	505	97.9% (95.9%; 99.9%)	89.3% (85.9%; 92.9%)	82.7% (78.4%; 87.2%)	78.0% (73.1%; 83.2%)	75.2% (69.6%; 81.2%)
	II	78	91.7% (84.6%; 99.4%)	77.6% (67.4%; 89.3%)	65.4% (53.8%; 79.5%)	64.2% (52.0%; 79.3%)	59.5% (46.2%; 76.7%)
	III	289	85.1% (80.7%; 89.8%)	61.4% (55.5%; 67.9%)	48.1% (42.0%; 55.2%)	42.4% (36.0%; 49.9%)	36.4% (29.9%; 44.3%)
	IV	270	55.9% (50.2%; 62.4%)	34.5% (29.0%; 41.1%)	25.5% (20.3%; 32.0%)	19.4% (14.6%; 25.9%)	12.9% (8.6%; 19.2%)
	X/NA	98	46.1% (36.7%; 57.8%)	27.3% (19.1%; 39.1%)	24.0% (16.2%; 35.6%)	20.7% (13.3%; 32.0%)	19.1% (11.8%; 30.9%)
Other and unspecified	All	2,923	78.3% (76.7%; 79.9%)	68.2% (66.3%; 70.1%)	63.0% (61.0%; 65.1%)	60.7% (58.5%; 62.9%)	59.1% (56.8%; 61.5%)
	I	1,448	94.4% (92.9%; 95.8%)	89.6% (87.5%; 91.6%)	85.9% (83.5%; 88.4%)	83.8% (81.1%; 86.6%)	82.1% (78.9%; 85.4%)
	II	189	78.2% (72.0%; 84.9%)	69.4% (62.3%; 77.4%)	65.8% (58.1%; 74.6%)	61.4% (53.1%; 70.9%)	58.7% (49.8%; 69.2%)
	III	406	75.3% (70.9%; 79.9%)	59.5% (54.5%; 65.0%)	49.3% (44.1%; 55.2%)	45.9% (40.4%; 52.1%)	43.6% (37.8%; 50.3%)

type	Stage	N at risk	Net Survival Probability, 2018-2022				
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	IV	468	42.4% (38.1%; 47.3%)	24.0% (20.3%; 28.4%)	17.4% (14.0%; 21.5%)	15.0% (11.7%; 19.1%)	13.8% (10.5%; 18.0%)
	X/NA	415	65.6% (60.8%; 70.7%)	51.6% (46.5%; 57.3%)	46.6% (41.3%; 52.5%)	44.4% (38.9%; 50.7%)	44.1% (38.3%; 50.8%)

5.1. Corpus uteri cancer survival trends: by tumour stage

5.1.1. Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2008-2022

Period	Stage	N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	**All**	7,213	91.6% (90.9%; 92.3%)	83.4% (82.3%; 84.5%)	79.8% (78.5%; 81.1%)
	I	4,533	98.5% (97.9%; 99.1%)	95.6% (94.6%; 96.7%)	93.8% (92.4%; 95.2%)
	II	429	94.4% (91.6%; 97.2%)	83.9% (79.4%; 88.8%)	75.9% (70.1%; 82.1%)
	III	710	83.5% (80.6%; 86.5%)	60.0% (56.1%; 64.2%)	51.6% (47.5%; 56.1%)
	IV	364	52.9% (47.9%; 58.5%)	28.2% (23.6%; 33.6%)	21.4% (17.2%; 26.6%)
	X/NA	1,181	81.0% (78.6%; 83.4%)	67.2% (64.2%; 70.4%)	62.3% (58.7%; 66.1%)
2013-2017	**All**	7,118	91.4% (90.6%; 92.1%)	83.6% (82.5%; 84.7%)	81.0% (79.7%; 82.3%)
	I	4,819	99.3% (98.8%; 99.8%)	96.7% (95.7%; 97.7%)	95.7% (94.4%; 97.1%)
	II	367	87.5% (83.7%; 91.4%)	77.4% (72.2%; 83.0%)	72.5% (66.3%; 79.2%)
	III	773	83.5% (80.7%; 86.4%)	62.7% (59.0%; 66.7%)	54.2% (50.0%; 58.8%)
	IV	515	52.4% (48.1%; 57.0%)	26.7% (22.9%; 31.0%)	21.5% (17.9%; 25.8%)
	X/NA	650	75.3% (71.7%; 79.0%)	59.9% (55.6%; 64.6%)	54.8% (50.0%; 60.1%)
2018-2022	**All**	6,879	91.0% (90.3%; 91.8%)	83.4% (82.2%; 84.6%)	80.9% (79.2%; 82.6%)
	I	4,660	99.4% (98.8%; 99.9%)	97.2% (96.1%; 98.3%)	96.4% (94.6%; 98.2%)
	II	375	92.8% (89.6%; 96.2%)	80.5% (75.1%; 86.3%)	78.2% (71.1%; 86.2%)
	III	857	85.3% (82.7%; 88.0%)	66.4% (62.6%; 70.5%)	59.1% (54.1%; 64.6%)

Period	Stage	Net Survival Probability					
		N at risk	1-y	(95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	609	50.1%	(46.2%; 54.4%)	27.1% (23.3%; 31.4%)	18.3% (14.2%; 23.6%)
	X/NA	380	65.8%	(60.8%; 71.2%)	44.6% (38.9%; 51.2%)	39.3% (32.7%; 47.2%)

5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage

5.2.1. Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2008-2022

Period	type	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
				Net Survival Probability		
2008-2012	Endometrioid carcinoma	**All**	4,948	96.3% (95.6%; 97.0%)	91.3% (90.1%; 92.4%)	88.5% (87.0%; 90.0%)
		I	3,536	99.7% (99.1%; 100.2%)	98.0% (96.9%; 99.1%)	96.9% (95.4%; 98.4%)
		II	299	98.4% (95.9%; 100.9%)	92.3% (87.5%; 97.4%)	85.0% (78.4%; 92.3%)
		III	400	87.4% (83.9%; 91.0%)	70.0% (65.1%; 75.3%)	61.6% (56.2%; 67.5%)
		IV	137	62.1% (54.2%; 71.1%)	39.8% (31.8%; 49.7%)	30.2% (22.8%; 40.1%)
		X/NA	576	89.1% (86.2%; 92.1%)	76.3% (72.1%; 80.8%)	71.1% (65.9%; 76.7%)
	Serous carcinoma	**All**	442	83.6% (79.9%; 87.5%)	56.7% (51.7%; 62.1%)	48.9% (43.6%; 54.8%)
		I	171	96.3% (92.5%; 100.3%)	83.1% (76.1%; 90.7%)	79.3% (70.9%; 88.8%)
		II	29	N<50	N<50	N<50
		III	111	80.8% (73.2%; 89.2%)	42.0% (33.1%; 53.3%)	29.8% (21.4%; 41.3%)
		IV	70	64.4% (53.8%; 77.1%)	28.5% (19.2%; 42.1%)	22.0% (13.7%; 35.1%)
		X/NA	61	70.6% (59.7%; 83.4%)	40.7% (29.6%; 56.0%)	33.4% (22.6%; 49.4%)
	Other and unspecified	**All**	1,829	80.7% (78.8%; 82.7%)	68.4% (66.0%; 70.9%)	63.7% (60.9%; 66.5%)
		I	827	94.0% (92.0%; 96.0%)	88.0% (85.0%; 91.0%)	83.6% (79.8%; 87.5%)
		II	101	82.9% (75.2%; 91.5%)	66.0% (56.0%; 77.9%)	58.7% (47.8%; 72.2%)
		III	199	77.1% (71.1%; 83.5%)	50.2% (43.2%; 58.4%)	43.8% (36.5%; 52.6%)
		IV	157	39.8% (32.7%; 48.4%)	18.0% (12.7%; 25.5%)	13.5% (8.8%; 20.8%)
		X/NA	546	73.3% (69.4%; 77.3%)	60.4% (56.0%; 65.2%)	56.1% (51.2%; 61.4%)
2013-2017	Endometrioid carcinoma	**All**	4,981	95.9% (95.2%; 96.6%)	92.5% (91.4%; 93.6%)	91.2% (89.8%; 92.7%)
		I	3,781	100.2% (99.7%; 100.7%)	99.5% (98.5%; 100.5%)	99.6% (98.2%; 101.1%)

Period	type	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	237	91.5% (87.3%; 95.8%)	84.4% (78.3%; 90.9%)	81.4% (73.9%; 89.6%)
		III	454	85.7% (82.2%; 89.3%)	73.5% (68.9%; 78.5%)	65.4% (60.0%; 71.4%)
		IV	171	56.8% (49.6%; 65.0%)	39.7% (32.6%; 48.3%)	36.1% (28.9%; 45.2%)
		X/NA	338	85.0% (80.8%; 89.5%)	72.2% (66.5%; 78.5%)	66.3% (59.5%; 73.8%)
	Serous carcinoma	All	565	82.6% (79.2%; 86.1%)	58.1% (53.7%; 62.9%)	48.4% (43.8%; 53.6%)
		I	246	97.9% (95.0%; 100.9%)	83.8% (78.1%; 90.1%)	76.2% (69.1%; 84.0%)
		II	33	N<50	N<50	N<50
		III	117	86.7% (80.1%; 93.8%)	45.5% (36.8%; 56.3%)	32.3% (24.1%; 43.4%)
		IV	115	61.2% (52.6%; 71.2%)	26.3% (19.0%; 36.4%)	15.1% (9.3%; 24.3%)
		X/NA	54	45.6% (33.6%; 61.8%)	37.0% (25.0%; 54.6%)	27.0% (16.3%; 44.9%)
	Other and unspecified	All	1,581	80.2% (78.1%; 82.3%)	64.8% (62.2%; 67.6%)	60.4% (57.4%; 63.6%)
		I	797	95.4% (93.6%; 97.3%)	87.6% (84.6%; 90.8%)	83.5% (79.6%; 87.6%)
		II	97	77.7% (69.2%; 87.1%)	67.7% (57.5%; 79.7%)	58.3% (47.0%; 72.3%)
		III	202	76.6% (70.6%; 83.1%)	48.4% (41.3%; 56.7%)	41.8% (34.3%; 50.9%)
		IV	230	44.5% (38.3%; 51.5%)	17.0% (12.7%; 22.9%)	13.8% (9.7%; 19.5%)
		X/NA	258	68.6% (62.7%; 75.0%)	48.7% (42.1%; 56.2%)	45.6% (38.5%; 53.9%)
2018-2022	Endometrioid carcinoma	All	4,867	96.7% (96.0%; 97.4%)	93.5% (92.3%; 94.7%)	92.0% (90.1%; 93.9%)
		I	3,753	100.6% (100.1%; 101.0%)	100.6% (99.5%; 101.7%)	100.7% (98.8%; 102.6%)
		II	238	97.9% (94.9%; 101.0%)	88.9% (82.8%; 95.4%)	87.9% (79.3%; 97.3%)
		III	481	90.6% (87.5%; 93.7%)	79.2% (74.4%; 84.2%)	71.4% (64.5%; 79.0%)
		IV	216	59.5% (53.0%; 66.7%)	38.3% (31.6%; 46.5%)	29.9% (22.1%; 40.5%)
		X/NA	179	75.0% (68.2%; 82.5%)	55.4% (46.7%; 65.6%)	43.7% (33.8%; 56.5%)
	Serous carcinoma	All	675	80.2% (77.0%; 83.6%)	55.2% (50.9%; 59.9%)	46.5% (41.1%; 52.7%)
		I	259	97.9% (95.0%; 100.7%)	81.3% (75.1%; 88.0%)	74.3% (65.4%; 84.5%)

The header "Net Survival Probability" spans the columns: N at risk, 1-y (95%CI), 3-y (95%CI), 5-y (95%CI).

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	45	N<50	N<50	N<50
		III	172	84.0% (78.2%; 90.3%)	50.3% (42.1%; 60.1%)	40.3% (30.6%; 53.1%)
		IV	155	52.1% (44.6%; 60.8%)	25.6% (18.9%; 34.8%)	8.9% (3.8%; 20.9%)
		X/NA	44	N<50	N<50	N<50
	Other and unspecified	All	1,342	76.0% (73.6%; 78.5%)	60.7% (57.7%; 63.9%)	57.6% (53.8%; 61.6%)
		I	651	93.1% (90.7%; 95.5%)	83.6% (79.7%; 87.6%)	80.3% (74.9%; 86.1%)
		II	92	78.7% (70.0%; 88.5%)	63.2% (52.0%; 76.8%)	60.4% (47.3%; 77.3%)
		III	204	74.0% (67.8%; 80.7%)	50.2% (42.8%; 59.0%)	46.2% (37.8%; 56.5%)
		IV	238	40.4% (34.5%; 47.3%)	17.4% (12.7%; 23.9%)	13.0% (8.3%; 20.3%)
		X/NA	157	60.7% (53.0%; 69.4%)	43.4% (35.1%; 53.6%)	42.1% (32.7%; 54.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Corpus uteri cancer mortality: by region

6.1.1. Corpus uteri cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Belgium	0	0	0	0	0	0	0	0	1	0	5	8	13	26	38	55	46	40	22	7	261	4.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[1.3]	[2.0]	[3.5]	[8.0]	[12.8]	[25.8]	[24.9]	[29.6]	[33.2]	[36.4]	[4.5]	(3.5; 4.5)
Brussels	0	0	0	0	0	0	0	0	0	0	1	1	3	0	5	3	0	5	1	0	19	3.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.7]	[3.0]	[10.1]	[0.0]	[23.2]	[18.5]	[0.0]	[49.2]	[17.4]	[0.0]	[3.1]	(2.0; 5.5)
Flanders	0	0	0	0	0	0	0	0	1	0	2	4	7	19	23	37	31	25	16	7	172	4.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[1.7]	[3.2]	[9.8]	[13.2]	[27.8]	[26.7]	[29.4]	[39.9]	[62.3]	[5.1]	(3.6; 4.9)
Wallonia	0	0	0	0	0	0	0	0	0	0	2	3	3	7	10	15	15	10	5	0	70	3.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[2.4]	[2.5]	[6.4]	[9.9]	[23.5]	[27.2]	[25.0]	[24.5]	[0.0]	[3.8]	(2.6; 4.3)

7.1. Corpus uteri cancer mortality trends: by region

7.1.1. Corpus uteri cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	181	186	181	190	219	200	209	201	188	214	228	209	230	232	237	233	227	261		
	CR	3.4	3.5	3.4	3.5	4.0	3.6	3.8	3.6	3.3	3.8	4.0	3.7	4.0	4.0	4.1	4.0	3.9	4.5		
	ESR2013	3.4	3.4	3.3	3.4	3.9	3.6	3.6	3.4	3.2	3.6	3.7	3.4	3.7	3.7	3.7	3.4	3.5	4.0	0.4 (-0.1; 0.9)	2004-2021
Brussels	**N**	18	14	14	17	21	11	7	17	17	12	14	15	21	15	14	15	16	19		
	CR	3.5	2.7	2.6	3.2	3.9	2.0	1.2	2.9	2.9	2.0	2.3	2.5	3.5	2.5	2.3	2.4	2.6	3.1		
	ESR2013	3.5	2.8	2.8	3.0	4.0	2.3	1.2	3.4	3.2	2.2	2.9	3.1	4.2	2.8	2.6	2.6	3.4	3.8	0.7 (-2.0; 3.4)	2004-2021
Flanders	**N**	118	132	129	136	154	141	151	138	130	152	166	143	149	162	163	161	151	172		
	CR	3.9	4.3	4.2	4.4	4.9	4.5	4.8	4.3	4.0	4.7	5.1	4.4	4.5	4.9	4.9	4.8	4.5	5.1		
	ESR2013	3.9	4.3	4.1	4.2	4.7	4.3	4.5	4.0	3.8	4.3	4.4	3.8	3.9	4.2	4.2	3.9	3.8	4.3	-0.3 (-0.8; 0.3)	2004-2021
Wallonia	**N**	45	40	38	37	44	48	51	46	41	50	48	51	60	55	60	57	60	70		
	CR	2.6	2.3	2.2	2.1	2.5	2.7	2.8	2.5	2.3	2.7	2.6	2.8	3.3	3.0	3.2	3.1	3.2	3.8		
	ESR2013	2.6	2.1	2.2	2.1	2.4	2.7	2.7	2.5	2.1	2.7	2.4	2.7	3.2	2.8	2.9	2.7	3.0	3.5	2.0 (1.0; 2.9)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024